T. S amp； Iacute； alcoh amp； oacute； Lica in one experimental body, including the administration of gevokizumab or 2-5 mg canakinumab per kilogram of body weight to a required experimental body； lt； P gt； current invention； oacute； n refers to M amp； eacute； eacute； all treatment or remission S amp； Iacute； alcoh amp； oacute； Lica in one experimental body, including the administration of gevokizumab or 2-5 mg canakinumab per kilogram of body weight to a required experimental body； lt； / P gt；<；p>；LA PRESENTE INVENCIÓ；N SE REFIERE A UN MÉ；TODO PARA TRATAR O ALIVIAR LOS SÍ；NTOMAS DE LA HEPATITIS ALCOHÓ；LICA EN UN SUJETO, QUE COMPRENDE ADMINISTRAR GEVOKIZUMAB O 2-5 MG DE CANAKINUMAB POR KG DE PESO CORPORAL A UN SUJETO QUE LO NECESITA.<；/p>；
